EYEN - eyenovia.com Total Enterprise Value

Brandmark of eyenovia.com (EYEN)

The market trend for Eyenovia, Inc. (EYEN) demonstrates an Enterprise Value of . The business relies on certified partners to ensure the seamless production of micro-dispensers within sterile zones. Eyenovia, Inc. (EYEN) maintains strong pricing power due to its patents on mist-based drug delivery technology. Meanwhile, demand for glaucoma therapy remains stable, rendering the company resilient to economic fluctuations and market cycles.

Eyenovia Inc. (EYEN) - Total Company Value from 07/04/2022 to 10/31/2026

Eyenovia (EYEN) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Eyenovia Inc.|EYEN - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Eyenovia|EYEN - Total Company Value
- book capitalization data:
Equity per Share Eyenovia|EYEN - Company Book Value|Market Capitalization to Net Assets eyenovia.com|EYEN - Company Total Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Eyenovia, Inc.|EYEN - Long-Term Debt to Capital|Short-Term Debt to Capital Eyenovia Inc.|EYEN - Company Debts|Debt to Net Assets Ratio Eyenovia|EYEN - Company Long-Term Debt|Company Current Liabilities Eyenovia|Quick Ratio eyenovia.com
- earnings and valuation multiples indicators:
EYEN - Net Income
Analysis of all company metrics:Eyenovia, Inc.
Brand item of Eyenovia

Enterprise Value (EV) sums market capitalization and net debt, determining the actual cost of acquiring a business while accounting for all liabilities and liquidity. The current total market valuation of Eyenovia, Inc. (EYEN) stands at , which, for a biopharmaceutical startup with outsourced production and a minimal environmental footprint, reflects the investment appeal of its intellectual property without the burden of heavy capital assets.

Competitors of Eyenovia, Inc. (EYEN)

Alcon Inc (ALC) - Total Enterprise Value|Bausch + Lomb Corp - Enterprise Value|Total Enterprise Value Glaukos Medical|Apellis Pharmaceuticals (APLS) - Total Company Value|Business Value BLTE|Total Company Value Ocular Therapeutix, Inc.|Harrow Inc - Full Business Value|Enterprise Value VRDN|LENZ (LENZ Corp) - Value Adjusted for Debt and Cash|Enterprise Value OCS (Oculis AG)|Enterprise Value eyepointpharma.com EYPT|KOD - Total Company Value|Value Adjusted for Debt and Cash ALDX (Aldeyra Therapeutics)|kalarx.com (KALA) - Total Company Value|Real Price to Acquire Entire Company Opus Genetics|OKYO (OKYO Pharma Ltd) - Enterprise Value|Enterprise Value Adverum|Real Price to Acquire Entire Company OTLK (Outlook Therapeutics, Inc.)|CLSD (Clearside Biomedical Inc) - Value Adjusted for Debt and Cash|Enterprise Value NBY (NovaBay Pharmaceuticals, Inc.)|Kiora Pharmaceuticals Inc. (KPRX) - Total Enterprise Value|ALIM: Real Price to Acquire Entire Company|Total Enterprise Value guardionhealth.com|OCUP: Enterprise Value|Total Enterprise Value Opthea Ltd (OPT)